Anti-infection silicon dioxide biological tissue adhesive and application thereof

A biological tissue, mesoporous silica technology, applied in the field of biomedicine, can solve the problems of toxic and side effects antibiotics, cross-infection, high incidence of infection, and achieve the effect of high activity and improved adhesion effect.

Active Publication Date: 2020-07-28
SHENYANG PHARMA UNIVERSITY
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] In addition, in most cases, trauma and infection always occur at the same time. Due to the impact of trauma environment and other factors, the incidence of post-injury infection is extremely high. At the same time, new secondary infection and cross-infection may be caused in the follow-up treatment
At present, the commonly used method to control bacterial infection is the application of antibiotics, but the antibacterial effect of antibiotics on local wounds is often limited, and there are also problems such as drug resistance, toxic side effects, and antibiotic abuse.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-infection silicon dioxide biological tissue adhesive and application thereof
  • Anti-infection silicon dioxide biological tissue adhesive and application thereof
  • Anti-infection silicon dioxide biological tissue adhesive and application thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0042] The preparation of example 1 mesoporous silica

[0043] sample 1

[0044]Weigh 0.3g CTAB into a 500mL three-necked bottle, add 96mL of distilled water, protect the inside of the reaction device with nitrogen gas, and stir it magnetically at 70°C for 1 hour to fully dissolve it. Measure 45mL of n-octane at a rate of 2 drops / second Drop into the above CTAB solution system. After dropping, continue to stir for 20 minutes to form a uniform emulsion. Measure 3.2 mL tetraethyl orthosilicate TEOS and drop it into the above solution at a rate of 2 drops / second. After dropping, weigh 0.066g of lysine and add to the above solution. Then measure 8.9 mL of methyl methacrylate monomer and drop it into the above solution at a rate of 2 drops / second. After the dropwise addition, 113.4 mg of azobisisobutylamidine hydrochloride AIBA was weighed and added to the reaction solution. After the addition was complete, the reaction was continued for 4 hours under magnetic stirring in a wa...

example 2

[0055] Example 2 Preparation of lysozyme-loaded mesoporous silica nanoparticles

[0056] Weigh 40 mg of lysozyme into a 10 mL vial, add 8 mL of PBS solution with pH 6.8, and stir magnetically at 200 rpm for 1 hour at 4°C to fully dissolve the lysozyme. Then, 20 mg of the mesoporous silica nanoparticles prepared in Example 1 were weighed and put into the above-mentioned lysozyme solution, and magnetically stirred at 200 rpm for 3 hours at 4°C. After stirring, centrifuge at 8000 rpm for 3 minutes, remove the supernatant, and obtain mesoporous silica nanoparticles loaded with lysozyme protein.

[0057] During the preparation process of the lysozyme-loaded mesoporous silica nanoparticles, samples were taken at 15 minutes, 30 minutes, 45 minutes, 1 hour, 1.5 hours, 2 hours, and 3 hours. The sampling method is as follows: absorb 500 μL of the stirring solution and centrifuge at 8000 rpm for 3 minutes, then take 200 μL of the supernatant and store it at 4° C. for testing. Prepare C...

example 3

[0060] Example 3 Carrying Lysozyme Mesoporous Silica Nanoparticle Drug Release Assay

[0061] Centrifuge the remaining solution at 8000rpm for 3 minutes after loading lysozyme in Example 2 for 3 minutes, transfer the solid precipitate to a 50mL flat-bottomed flask, add 25mL of pH6.8 phosphate buffer, stir magnetically in a 37°C water bath, and release medicine 24 hours. Samples were taken at 15 minutes, 30 minutes, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, and 5 hours. The sampling method is as follows: absorb 1000 μL of the stirring solution and centrifuge at 8000 rpm for 3 minutes, then take 500 μL of the supernatant and store it at 4°C for testing, add 500 μL of PBS with pH 6.8 to the remaining liquid and solid, blow well, and add back to release the drug system.

[0062] Mix and shake the 500 μL supernatant obtained at each time point with the Coomassie Brilliant Blue staining solution described in Example 2, and after dark staining for 3 minutes, test the UV-Vis abs...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
pore sizeaaaaaaaaaa
specific surface areaaaaaaaaaaa
Login to view more

Abstract

The invention relates to a preparation method of a drug-loaded antibacterial nano mesoporous silicon dioxide biological tissue adhesive and an application thereof in tissue adhesion. The preparation method of the drug-loaded mesoporous silicon dioxide comprises the following steps of preparing an oil-in-water emulsion from n-octane, cetyltrimethylammonium bromide and water, polymerizing a styrenemonomer and an ethyl orthosilicate monomer in an oil-phase liquid drop, and carrying out demulsifying, centrifuging, and high-temperature calcining to remove styrene, thereby obtaining mesoporous silicon dioxide nanoparticles; and adding the prepared silicon dioxide into a lysozyme solution to load lysozyme, and performing centrifuging and drying to obtain the anti-infection silicon dioxide biological tissue adhesive. The invention aims to overcome the defects of secondary injury caused by surgical suture or limitation that some organ tissues are not suitable for suture, poor effect of a traditional organic biological adhesive and the like in wound treatment. The adhesive has the advantages of quick action, no secondary trauma and the like, and has a wide application prospect in the fieldof wound treatment.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a preparation method and application of a novel bioadhesive, in particular to the preparation and application of an anti-infection nanometer mesoporous silica loaded with lysozyme. Background technique [0002] Injuries such as chronic non-healing wounds and visceral surgical incisions place a heavy burden on patients and healthcare systems. At present, surgical sutures and polymer adhesives are usually used as treatment methods for wounds caused by visceral operations such as liver, lung, and heart. However, for soft tissues such as the liver and lungs, surgical suturing will cause certain damage to the organs and leave gaps in the incision; polymer adhesives are also limited due to their limited effect in a humid internal environment and the ability to control polymerization or crosslinking in the body. The reaction conditions are too complex and other reasons limit its application ran...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61L24/10A61L24/02A61L24/00
CPCA61L24/108A61L24/02A61L24/0015A61L24/001A61L2300/404A61L2400/12A61L2300/254A61L2300/602A61L2300/412Y02A50/30
Inventor 高亦鲲王思玲林伟康刘迎春
Owner SHENYANG PHARMA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products